Medulloblastoma (MB) is the most common pediatric brain tumour and usually affects children and infants under 10 years old. Current treatment for MB involves aggressive chemotherapy and radiation, which can lead to harmful long-term side effects, including cognitive impairment, endocrine disorders and an increased risk of secondary cancers later in life.